CNBC's Meg Tirrell reports details from Amgen's earnings conference call, including what CEO Robert Bradway has to say. The "Fast Money" traders weigh in on the biotech sector.
Earnings are out for Amgen. CNBC's Meg Tirrell reports the details.
John Fichthorn, Dialectic Capital co-founder, discusses why he is short Express Scripts.
For many, Theranos and Elizabeth Holmes represented a promise that disease could be caught sooner, NBC News reports.
Novozymes CEO, Peder Holk Nielsen talks about its agricultural business with comment on the impending Bayer Monsanto deal and future innovations.
Novozymes CEO, Peder Holk Nielsen reflects upon the biotechnology firm’s latest earnings, which missed market expectations.
CNBC's Meg Tirrell reports the latest news in pharma, including Novartis under pressure, and Merck's FDA drug approval.
Jim Chanos, Kynikos Associates President and founder, explains why he is short Valeant Pharmaceuticals.
Bill Miller, LMM Investments, shares his take on Valeant and energy stocks.
Shares of Alkermes are soaring after releasing positive results on an experimental depression drug. CNBC's Meg Tirrell reports.
Ed Yardeni, Yardeni Research president, discusses how he sees next month's election playing out in the markets.
Arie Belldegrun, Kite Pharma CEO talks to CNBC's Meg Tirrell about developing cancer immunotherapy drugs with T-cells. Also Belldegrun address the question about pricing the product once it comes to market.
Martin Shkreli heads back to court to face charges of looting his former biotech firm and pay back defrauded investors, reports CNBC's Meg Tirrell.
The "Fast Money Halftime Report" traders, Kevin O'Leary, O'Shares Chairman and "Shark Tank" star, and Ian Winer, Wedbush, share their takes on the health care sector, including Merck after Bank of America's call to upgrade the stock to buy.
CNBC's Bertha Coombs reports the latest troubles in health care, including why shares of Humana are sinking.
Chris Raymond, Raymond James analyst, discusses how to trade the biotech sell-off amid election season.
CNBC's Meg Tirrell discusses the latest moves in health care, and how politics is weighing on the sentiment in the space.
John Crowley, CEO of Amicus Therapeutics, discusses his biotechnology business model, as well as drugs pricing.
Jim Cramer says uncertainty surrounding a Democratic win for the White House puts drug stocks in the danger zone.
The "Fast Money" traders discuss the trade on biotech stocks, with healthcare being the worst-performing sector today.